BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21985541)

  • 1. Peroxisome proliferator-activated receptor-γ and the endothelium: implications in cardiovascular disease.
    Magri CJ; Gatt N; Xuereb RG; Fava S
    Expert Rev Cardiovasc Ther; 2011 Oct; 9(10):1279-94. PubMed ID: 21985541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
    Marx N; Duez H; Fruchart JC; Staels B
    Circ Res; 2004 May; 94(9):1168-78. PubMed ID: 15142970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Protective role of PPARgamma agonists against cardiovascular disease].
    Yamagishi S
    Nihon Rinsho; 2010 Feb; 68(2):307-11. PubMed ID: 20158101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Narrowing in on cardiovascular disease: the atheroprotective role of peroxisome proliferator-activated receptor gamma.
    Gerry JM; Pascual G
    Trends Cardiovasc Med; 2008 Feb; 18(2):39-44. PubMed ID: 18308193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
    Belvisi MG; Hele DJ; Birrell MA
    Eur J Pharmacol; 2006 Mar; 533(1-3):101-9. PubMed ID: 16458290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular effects of PPARgamma activators - from bench to bedside.
    Marx N; Walcher D
    Prog Lipid Res; 2007 Nov; 46(6):283-96. PubMed ID: 17637478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells.
    Ogawa D; Nomiyama T; Nakamachi T; Heywood EB; Stone JF; Berger JP; Law RE; Bruemmer D
    Circ Res; 2006 Apr; 98(7):e50-9. PubMed ID: 16556873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B; Fonseca V
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock.
    Abdelrahman M; Sivarajah A; Thiemermann C
    Cardiovasc Res; 2005 Mar; 65(4):772-81. PubMed ID: 15721857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism.
    Biscetti F; Gaetani E; Flex A; Aprahamian T; Hopkins T; Straface G; Pecorini G; Stigliano E; Smith RC; Angelini F; Castellot JJ; Pola R
    Diabetes; 2008 May; 57(5):1394-404. PubMed ID: 18268046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of 15-deoxy-delta(12,14)-prostaglandin J(2), an endogenous ligand of peroxisome proliferator-activated receptor gamma, in tumor angiogenesis.
    Kim EH; Surh YJ
    Biochem Pharmacol; 2008 Dec; 76(11):1544-53. PubMed ID: 18771658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?
    Han S; Roman J
    Anticancer Drugs; 2007 Mar; 18(3):237-44. PubMed ID: 17264754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma.
    Park SJ; Lee YC
    J Asthma; 2008; 45(1):1-8. PubMed ID: 18259989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins.
    Tesse A; Al-Massarani G; Wangensteen R; Reitenbach S; Martínez MC; Andriantsitohaina R
    J Pharmacol Exp Ther; 2008 Feb; 324(2):539-47. PubMed ID: 18039959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.
    Lee KS; Kim SR; Park SJ; Park HS; Min KH; Jin SM; Lee MK; Kim UH; Lee YC
    J Allergy Clin Immunol; 2006 Jul; 118(1):120-7. PubMed ID: 16815147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.
    Yang J; Zhang D; Li J; Zhang X; Fan F; Guan Y
    Clin Sci (Lond); 2009 Jan; 116(1):17-26. PubMed ID: 19037881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.